Compare Amylx Pharmaceuticals Inc (AMLX) vs ConocoPhillips (COP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs ConocoPhillips — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while ConocoPhillips trades at $111.13 (market cap $132.84B). The key difference: ConocoPhillips is far larger — about 67.1× Amylx Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 3.08% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | COP | |
|---|---|---|
Market Cap | $1.98B | $132.84B |
Sector | Health | Energy |
52-Week High | $18.70 | $133.80 |
52-Week Low | $7.64 | $85.66 |
Enterprise Value | $1.70B | $149.81B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
ConocoPhillips (COP) trades at $109.04, up 0.94% with a bullish technical signal despite mixed moving averages. The company maintains solid fundamentals with $58.94B revenue, 12.58% net margin, and consistent cash flow generation. Recent earnings show beats in Q3 2025 and Q1 2026, while analysts project strong Q2 2026 EPS of $2.85. The stock offers a dividend yield with recent $0.84 payout, supported by 74.51% buy ratings from coverage analysts.
COP presents a compelling value opportunity with P/E of 18.48 and EV/EBITDA of 6.08 below sector averages. The consensus price target of $137.14 implies 26% upside potential. Key risks include oil price volatility, geopolitical tensions affecting Middle East supply, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The upcoming Q2 earnings on August 6, 2026, will be crucial for validating growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
